The Novo Nordisk partnership ending does not alter my long-term bullish thesis on HIMS; the company is much more than just a GLP-1 play. HIMS' core value lies in its broad treatment offerings and disruptive model, not in partnerships with big pharma like NVO. Legal risks remain, but I believe HIMS is well-positioned to defend itself, and no legal action has been initiated by NVO yet.
This morning, the Danish pharmaceutical giant Novo Nordisk announced the abrupt end of its brief partnership with telehealth company Hims & Hers Health (NYSE: HIMS), citing concerns over Hims & Hers' “knockoff” weight-loss drugs. Now, Hims & Hers' shares are plummeting as investors react to the news.
It's not often that investors come across the kind of companies that can yield a multi-bagger investment over the years. Still, today, there is one name that possesses all the right components (and timing) to make it a suitable investment for those seeking to compound their wealth in the coming years.
Household & Personal Products Industry | Consumer Defensive Sector | Mr. Andrew Dudum CEO | XSTU Exchange | US4330001060 ISIN |
US Country | 1,637 Employees | - Last Dividend | - Last Split | 13 Sep 2019 IPO Date |
Hims & Hers Health, Inc., based in San Francisco, California, operates as a telehealth platform connecting consumers with licensed healthcare professionals across the United States, the United Kingdom, and other international locations. The company leverages its websites and mobile application to offer a variety of carefully selected health and wellness products and services, both on prescription and over-the-counter basis. Its business model focuses on providing convenient access to ongoing healthcare services, including prescription medication refills and consultations with healthcare providers, as well as a wide range of wellness products through direct sales and wholesale partnerships.